Another armed CD4+ T cell ready to battle hepatocellular carcinoma

Hepatology

Volumn 58, Issue 1, 2013, Pages 1-3

  Cabrera, Roniel ^a   Szabo, Gyongyi ^b  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTAGLANDIN; TRANSFORMING GROWTH FACTOR BETA;

ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CYTOKINE PRODUCTION; DENDRITIC CELL; HEPATITIS B; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MACROPHAGE; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; TUMOR CELL; TUMOR IMMUNOLOGY; TUMOR MICROENVIRONMENT;

CARCINOMA, HEPATOCELLULAR; CD4-POSITIVE T-LYMPHOCYTES; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; HEPATITIS B, CHRONIC; HUMANS; LIVER NEOPLASMS; MALE; T-LYMPHOCYTES, CYTOTOXIC;

EID: 84879603220     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.26377     Document Type: Article

References (13)

1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-674. Review.
2. Unitt E, Rushbrook SM, Marshall A, Davies S, Gibbs P, Morris LS et al. Compromised lymphocytes infiltrate hepatocellular carcinoma: the role of T-regulatory cells. Hepatology 2005: 41: 722-730.
3. Cabrera R, Cao M, Xu Y, Firpi R, Zhu H, Liu C, et al. Hepatocellular carcinoma cell supernatants increase expansion and function of CD4(+)CD25(+) regulatory T cells. Lab Invest 2007; 87: 582-590.
4. Hoechst B, Ormandy LA, Ballmaier M, Lehner F, Krüger C, Manns MP, et al. A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells. Gastroenterology 2008; 135: 234-243.
5. Zhou J, Ding T, Pan W, Zhu LY, Li L, Zheng L. Increased intratumoral regulatory T cells are related to intratumoral macrophages and poor prognosis in hepatocellular carcinoma patients. Int J Cancer 2009; 125: 1640-1648.
6. Cai L, Zhang Z, Zhou L, Wang H, Fu J, Zhang S, et al. Functional impairment in circulating and intrahepatic NK cells and relative mechanism in hepatocellular carcinoma patients. Clin Immunol 2008; 129: 428-437.
7. Cabrera R, Ararat M, Cao M, Xu Y, Wasserfall C, Atkinson MA, et al. Hepatocellular carcinoma immunopathogenesis: clinical evidence for global T cell defects and an immunomodulatory role for soluble CD25 (sCD25). Dig Dis Sci 2010; 55: 484-495.
8. Fu J, Xu D, Liu Z, Shi M, Zhao P, Fu B, et al. Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients. Gastroenterology 2007; 132: 2328-2339.
9. Fu J, Zhang Z, Zhou L, Qi Z, Xing S, Lv J, et al. Impairment of CD4+ cytotoxic T cells predicts poor survival and high recurrence rates in patients with hepatocellular carcinoma. Hepatology 2013; 58: 139-149.
10. Appay V, Zaunders JJ, Papagno L, Sutton J, Jaramillo A, Waters A, et al. Characterization of CD4(+) CTLs ex vivo. J Immunol 2002; 168: 5954-5958.
11. Aslan N, Yurdaydin C, Wiegand J, Greten T, Ciner A, Meyer MF, et al. Cytotoxic CD4 T cells in viral hepatitis. J Viral Hepat 2006; 13: 505-514.
12. Bruix J, Sherman M; American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53: 1020-1022.
13. Prieto PA, Yang JC, Sherry RM, Hughes MS, Kammula US, White DE, et al. CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma. Clin Cancer Res 2012; 18: 2039-2047.